The more recent emergence of MET antibodies including the bispecific antibody, amivantamab, is expanding upon available treatment options and is currently being studied as potential first-line therapy for EGFR-mutant NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.